![2MM: AI Roundup- AI Cancer Test, Smarter Hospitals, Faster Drug Discovery, and Mental Health Tech [May 2nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/Untitled-design-350x250.png)
Artificial intelligence predicts colorectal cancer in ulcerative colitis with 99% accuracy
1. A new AI workflow utilizing large language models can predict with 99% accuracy which ulcerative colitis patients will remain ...
Tag: Ulcerative Colitis
The incidence of hypertension and infections may increase with age among patients with ulcerative colitis treated with ozanimod
1. Incidence rates of hypertension and opportunistic and serious infections increase with age in patients receiving ozanimod for ulcerative colitis ...
2 Minute Medicine Rewind November 24, 2025
Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age 1. Incidence rates ...
The incidence of ocular manifestations is higher in patients with Crohn’s disease compared to ulcerative colitis
1. Among patients with adult-onset inflammatory bowel disease (IBD), the incidence of ocular manifestations was 2.9 per 1000 person-years. 2. ...
Ustekinumab may be superior to Vedolizumab for the treatment of Crohn’s disease
1. In patients with Crohn’s disease (CD) of the pouch following ileal-pouch anal anastomosis (IPAA) for medically-refractory ulcerative colitis (UC), ...
Fecal calprotectin is a useful marker for defining small bowel endoscopic remission in Crohn’s disease
1. In patients with Crohn’s disease (CD), fecal calprotectin (FC) was a useful biomarker for monitoring small bowel lesions and ...
Rectoscopy alone may be sufficient to evaluate for remission of ulcerative colitis
1. Rectoscopy alone for evaluation of endoscopic and histologic remission of ulcerative colitis (UC) had good accuracy and is sufficient ...
Inflammatory bowel disease may be associated with increased risk of osteoporosis and osteopeia
1. In postmenopausal patients with ulcerative colitis (UC) or Crohn’s disease (CD), approximately one-third had osteoporosis while approximately 40% had ...
Mirikizumab is safe and effective in patients with moderate-to-severe Crohn’s disease
1. The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus placebo. 2. Clinical remission ...
Fecal Microbiota, live-jslm may be an effective means of preventing Clostridiodes difficile infections in patients with inflammatory bowel disease
1. The use of fecal microbiota, live-jslm (RBL; REBYOTA®) in the prevention of recurrent Clostridioides difficile infection (rCDI) in patients ...
